No Data
No Data
No Data
No Data
No Data
AdAlta Ltd Advances Cellular Immunotherapy Innovations
TipRanksApr 10 07:38
AdAlta Explores Cancer Immunotherapies Joint Venture for Western Market
AdAlta (ASX:1AD) signed a memorandum of understanding with SYNthesis BioVentures Fund to provide innovative cellular immunotherapies from Asia to the Western market through a joint entity, according to a Monday filing with the Australian bourse.
MT NewswiresApr 8 13:26
AdAlta Ltd: Pioneering Next-Gen Cancer Immunotherapies
TipRanksApr 8 08:37
AdAlta's AD-214 Demonstrates Safety and Efficacy Potential for Fibrotic Disease Treatment
Top-line results from a Phase I extension study of AdAlta’s (ASX: 1AD) lead asset AD-214 in the treatment of fibrotic disease have established the safety, tolerability and bioavailability of a target dose for planned Phase II clinical studies.
Small CapsMar 6 09:07
Stocks of the Hour: Atomo Diagnostics, AdAlta, Aruma Resources
To register for Friday's webinar click here.Atomo Diagnostics (ASX:AT1) has announced securing purchase orders from Viatris Healthcare Pty Ltd for approximately AUD $970,000 worth of HIV Self-Tests, m
sharecafeMar 6 08:50
AdAlta-La Trobe University Collab Discovers New I-Bodies for Malaria Treatment; Shares Climb 4%
AdAlta's (ASX:1AD) research collaboration with La Trobe University discovered a new family of i-bodies that protect cells from invasion by malaria and related parasites, the drug development firm said Tuesday.
MT NewswiresDec 19, 2023 08:11
No Data
No Data